Biogen Idec (BIIB) Shares Given a "Neutral" Rating by JPMorgan Chase & Co ... LocalizedUSA It includes BG-12, Daclizumab, Fampridine, GA101, Humanized Anti-CD20 MAb (ocrelizumab), Lixiavaptan, Long-Acting rFactor IX and PEGylated interferon beta-1a. Shares of Biogen Idec traded up 2.21% during mid-day trading on Thursday, hitting $100.94. ... |
